Johannes D. Schultheiss

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Univariate- and machine learning-based plasma metabolite signature differentiates PSC-IBD from IBD and is predicted to be driven by gut microbial changes.

Univariate- and machine learning-based plasma metabolite signature differentiates PSC-IBD from IBD and is predicted to be driven by gut microbial changes.

Journal: Metabolomics : Official journal of the Metabolomic Society

Published: December 22, 2025

Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease.

Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease.

Journal: Gut microbes

Published: August 21, 2024

Reply.

Reply.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: March 29, 2022

Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.

Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: January 29, 2022

Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases - the longer the less? Authors' reply.

Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases - the longer the less? Authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: December 31, 2021

Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease.

Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease.

Journal: Alimentary pharmacology & therapeutics

Published: May 07, 2021

Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.

Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.

Journal: Inflammatory bowel diseases

Published: November 17, 2020

Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container.

Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container.

Journal: Digestive diseases and sciences

Published: February 14, 2020

Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.

Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.

Journal: Alimentary pharmacology & therapeutics

Published: January 03, 2019

Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review.

Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review.

Journal: Digestion

Published: October 01, 2018

Showing 1-10 of 10

Last Updated: 09/26/2026